| Dr Nicole A Rush, OD | |
|
1095 Alabama Ave., Bandon, OR 97411 | |
| (541) 347-3622 | |
| (541) 347-2872 |
| Full Name | Dr Nicole A Rush |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 23 Years |
| Location | 1095 Alabama Ave., Bandon, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467400952 | NPI | - | NPPES |
| 227958 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2856ATI (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coos Eye Centers Inc | 0547254724 | 3 |
News Archive
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.
BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
Researchers at the University of Maryland have identified how the pathogenic bacterium Pseudomonas aeruginosa uses tension-activated membrane channels to stop itself from swelling up and bursting when it is suddenly exposed to water.
› Verified 3 days ago
| Provider Name | Coos Eye Centers Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508069428 PECOS PAC ID: 0547254724 Enrollment ID: O20040412000538 |
News Archive
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.
BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
Researchers at the University of Maryland have identified how the pathogenic bacterium Pseudomonas aeruginosa uses tension-activated membrane channels to stop itself from swelling up and bursting when it is suddenly exposed to water.
› Verified 3 days ago
| Provider Name | Curry Eye Centers, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1548390206 PECOS PAC ID: 7315910676 Enrollment ID: O20040816000244 |
News Archive
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.
BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
Researchers at the University of Maryland have identified how the pathogenic bacterium Pseudomonas aeruginosa uses tension-activated membrane channels to stop itself from swelling up and bursting when it is suddenly exposed to water.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicole A Rush, OD P.o. Box 956, Bandon, OR 97411 Ph: (541) 347-3622 | Dr Nicole A Rush, OD 1095 Alabama Ave., Bandon, OR 97411 Ph: (541) 347-3622 |
News Archive
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.
BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
Researchers at the University of Maryland have identified how the pathogenic bacterium Pseudomonas aeruginosa uses tension-activated membrane channels to stop itself from swelling up and bursting when it is suddenly exposed to water.
› Verified 3 days ago
Bandon Vision Center Optometrist Medicare: Medicare Enrolled Practice Location: 1095 Alabama Avenue, Bandon, OR 97411 Phone: 541-347-3622 Fax: 541-347-2872 |